Test Description

How Immunoassay UDS Works

Standard urine drug screens use immunoassay technology — antibodies designed to bind specific drug metabolites or structural analogs. When the concentration exceeds a predetermined cutoff threshold, the test reports positive. These tests detect drug classes, not specific drugs.

What the Standard Panel Tests For

  • Amphetamines (cutoff typically 1,000 ng/mL)
  • Barbiturates (cutoff 200 ng/mL)
  • Benzodiazepines (cutoff 200 ng/mL)
  • Cocaine metabolite (benzoylecgonine; cutoff 150-300 ng/mL)
  • Marijuana/THC (THC-COOH; cutoff 50 ng/mL)
  • Opiates (morphine/codeine; cutoff 300 ng/mL or 2,000 ng/mL)
  • Phencyclidine (PCP) (cutoff 25 ng/mL)
The standard "opiate" immunoassay only reliably detects morphine, codeine, and heroin metabolites. It does NOT detect fentanyl, methadone, buprenorphine, tramadol, or most synthetic opioids. A negative opiate screen in an opioid overdose is EXPECTED if the patient used fentanyl.
Quick Reference
  • Type: Qualitative immunoassay (positive/negative per drug class)
  • Standard Panel Includes: Amphetamines, barbiturates, benzodiazepines, cocaine, marijuana (THC), opiates, PCP; expanded panels may add methadone, oxycodone, buprenorphine, fentanyl
  • Turnaround: Minutes to hours (point-of-care or lab-based)
  • Confirmation: Gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS)
  • Critical Limitation: HIGH false positive and false negative rates; does NOT detect many synthetic opioids (fentanyl), novel psychoactive substances, or many benzodiazepines
  • Key Point: The UDS rarely changes acute management in the ED; treat the toxidrome, not the test
Detection Windows
Swipe to see more
Drug Class Detection Window Notes
Amphetamines 1-3 days Methamphetamine detectable longer than amphetamine
Barbiturates Short-acting: 1-4 days; Long-acting: 2-3 weeks Phenobarbital may be detectable for weeks
Benzodiazepines Short-acting: 1-3 days; Long-acting: up to 30 days Many newer benzos NOT detected (see false negatives)
Cocaine 2-4 days (heavy use up to 14 days) Detects benzoylecgonine metabolite; very few false positives
Marijuana (THC) Occasional: 3-7 days; Chronic: 15-30+ days Fat-soluble; very long detection in heavy users
Opiates 1-3 days Detects morphine/codeine; NOT fentanyl or synthetics
PCP 3-7 days (heavy use up to 30 days) Many cross-reactants (see false positives)
Common False Positives

False positives are extremely common with immunoassay screens due to structural cross-reactivity:

Swipe to see more
Drug Class Common False Positive Causes
Amphetamines Pseudoephedrine, phenylephrine, bupropion, labetalol, ranitidine, trazodone, phentermine, selegiline, MDMA, lisdexamfetamine
Benzodiazepines Sertraline, efavirenz, oxaprozin
Marijuana (THC) Dronabinol (synthetic THC — true positive technically), hemp products (CBD oils with trace THC), NSAIDs (rare with modern assays), efavirenz
Opiates Poppy seeds (true positive — contains morphine/codeine), dextromethorphan, rifampin, quinolones (older assays)
PCP Dextromethorphan, diphenhydramine, tramadol, ketamine, venlafaxine, lamotrigine
Methadone Quetiapine, diphenhydramine, verapamil (assay-dependent)
Cocaine is the most reliable result on UDS. The immunoassay for benzoylecgonine (cocaine metabolite) has very few cross-reactants. A positive cocaine result is almost always a true positive.
Critical False Negatives

These are clinically dangerous because important drugs are NOT detected by the standard panel:

Opioids NOT Detected by Standard "Opiate" Screen

  • Fentanyl and analogs (requires specific fentanyl immunoassay)
  • Methadone (requires specific methadone assay)
  • Buprenorphine (requires specific assay)
  • Tramadol
  • Oxycodone (may be missed at standard cutoffs; many labs now add a separate oxycodone assay)
  • Hydromorphone (inconsistently detected)
  • Meperidine

Benzodiazepines NOT Detected or Poorly Detected

  • Clonazepam (poorly detected — metabolite 7-aminoclonazepam does not cross-react well)
  • Lorazepam (glucuronide metabolite often missed)
  • Alprazolam (inconsistently detected at low doses)
  • Midazolam (may not be detected)
  • Flunitrazepam (Rohypnol)

Other Important Substances NOT on Standard Panel

  • Synthetic cannabinoids (K2/Spice)
  • Bath salts (synthetic cathinones)
  • GHB (gamma-hydroxybutyrate)
  • LSD
  • Psilocybin/psilocin
  • Novel psychoactive substances
In the fentanyl era, a negative "opiate" screen is meaningless for ruling out opioid toxicity. If the clinical picture looks like opioid toxicity (miosis, respiratory depression, decreased consciousness), treat with naloxone regardless of the UDS result. The test does not detect fentanyl.
Clinical Pearls
"Treat the patient, not the test": The UDS rarely changes acute ED management. If a patient presents with a toxidrome (opioid, sympathomimetic, anticholinergic, etc.), treat the toxidrome. Do not wait for UDS results to give naloxone or manage agitation.
Positive UDS ≠ "intoxicated": A positive marijuana screen may reflect use days to weeks prior. A positive benzodiazepine screen may be from a prescribed medication. The UDS tells you the patient was EXPOSED to a substance, not that it is causing their current symptoms.
When UDS IS clinically useful: The UDS can be helpful for confirming a suspected exposure when the toxidrome is unclear, identifying unexpected co-ingestants, psychiatric evaluation context, and child welfare assessments. It should inform, not dictate, clinical decision-making.
Know your lab's specific assay. Different hospitals use different immunoassay platforms with different cross-reactivity profiles and cutoff thresholds. What causes a false positive at one institution may not at another. Familiarize yourself with your institution's specific assay.
Confirmation testing: GC-MS or LC-MS/MS provides definitive identification of specific compounds and is the gold standard. However, it takes hours to days and is not useful for acute management. It is important for medicolegal situations, employment testing, and cases where false positive has clinical consequences.
Poppy seeds can cause true morphine/codeine positive: FDA testing has confirmed that poppy seeds contain enough morphine and codeine to trigger a positive opiate screen. This is a true positive for the drug (not a cross-reactant), though it does not indicate illicit use.
References
  1. Moeller, K. E., Kissack, J. C., Atayee, R. S., & Lee, K. C. (2017). Clinical interpretation of urine drug tests: what clinicians need to know about urine drug screens. Mayo Clinic Proceedings, 92(5), 774-796.
  2. Brahm, N. C., et al. (2010). Commonly prescribed medications and potential false-positive urine drug screens. American Journal of Health-System Pharmacy, 67(16), 1344-1350.
  3. Saitman, A., Park, H. D., & Fitzgerald, R. L. (2014). False-positive interferences of common urine drug screen immunoassays: a review. Journal of Analytical Toxicology, 38(7), 387-396.
  4. Farkas, Josh MD. (2015). Urine drug screen pitfalls. EMCrit Project — Internet Book of Critical Care.
  5. Nickson, C. (n.d.). Urine drug screen. Life in the Fast Lane (LITFL).
Back to Toxicology Panel All Lab Values
Medical Disclaimer
  • For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
  • Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
  • Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
The clinical content and references are curated and reviewed by myself; however, AI was used to assist in organizing, paraphrasing, and formatting the information presented.